Become A Featured Company

Why Micropropagation is the Future of Cannabis Cultivation

Ryan Allway

April 10th, 2018

Exclusive, News, Top Story

The cannabis industry is projected to exceed $50 billion by 2026, according to Cowen & Co., driven by the legalization of medical and adult-use cannabis throughout the United States. While most companies are focused on cultivation and retail sales, there are some companies focused on making the industry safer, better, and more efficient. The techniques pioneered by these companies are becoming increasingly necessary to help the industry scale to meet demand.

Segra International Corp. is a pioneer in micropropagation, also known as plant tissue culture, which is designed to help cultivators increase their yields, reduce harmful pathogens, and ultimately help scale production to meet growing medical and adult-use demand worldwide. The company plans to go public later in 2018.

Click here to receive Segra International updates prior to the company going public.

How Most Cannabis is Grown

You might think of seeds as the natural starting point for growing plants, but growing a plant from a seed takes a long time and each resulting plant is different.

Large-scale commercial cannabis cultivators prefer to use clones, or genetically identical plantlets, derived from mother plant cuttings or other methods. By cutting a healthy lower branch, placing it immediately into water, and transporting the clone into soil, these cultivators can grow genetically identical plants. The clones have a much shorter growing window than plants derived from seeds, while each plant has identical cannabinoid and terpene ratios.

The problem is that this approach is labor intensive and requires a lot of physical space to maintain mother plants. This space for mother plants and cloning could otherwise be used for production and generate revenue if not required for nursery operations. In addition, mother plants have a finite lifespan and are more susceptible to pathogens as a result of their long residence times. Any clones derived from a pathogen-carrying mother plant will have the same infections and carry those into the vegetative and flowering stages of production. All of this means that the current process is not efficient, safe, or scalable and could lead to complete crop (and strain) loss in the event of an uncontrollable pathogen outbreak – a cultivator’s worst nightmare.

Why Micropropagation?

Many traditional agricultural crops have faced these same issues, but they have managed to effectively scale using a tissue culture technique known as micropropagation.

Micropropagation is a method of plant propagation using extremely small pieces of plant tissue taken from a carefully chosen and prepared mother plant, and rapidly growing these under sterile laboratory conditions to produce new plants.

Most plantlets produced this way are sold at the rooting stage when the plantlet is ready to be acclimated the final growing environment. Commercial cannabis cultivators can purchase these plantlets and acclimate them to their unique growing environment before moving them into the main greenhouse. This process takes very little time compared to the time it takes to grow a plant from a seed or clone a plant from cuttings from a mother plant.

Gaining Traction Among LPs

Many licensed producers are embracing tissue culture techniques and micropropagation as a way to dramatically lower their costs, reduce the risk of pathogens, and ensure the best products for patients and consumers. In fact, LPs can effectively increase their productive square footage by five to 20 percent by eliminating the space that was used for mothering plants. They can also avoid pathogens without the use of pesticides, creating cleaner and safer products.

Segra International’s recent partnership with The Hydropothecary Corporation (TSX-V: THCX) is a perfect example of these benefits. Under the terms of the deal, Segra will provide its expertise and unique tissue culture techniques to help the licensed producer scale up its operations to meet market demand in Canada’s upcoming recreational market this summer. The partnership is expected to rapidly scale into millions of plantlets per year.

“Working with Segra will allow us to meet one of the biggest challenges as we meet the demand for cannabis products across Canada and beyond, balancing quality and quantity in our cannabis production,” said Hydropothecary CEO Sebastien St-Louis. “Thanks to Segra’s plant tissue culture technique, we will scale up our production process while maintaining the industry-leading quality standards that have made us so successful.”

Click here to receive Segra International updates prior to the company going public.

Looking Ahead

Segra International Corp. is targeting a major pain point for licensed producers and is developing micropropagation labs to deliver tens of millions of plantlets to LPs across Canada. The company plans to go public later in 2018.

Segra’s world-class management team includes Director of Tissue Culture, Dr. Sma Zobayed, a leading specialist in plant tissue culture with two patents related to the subject and over 50 published scientific papers; Chief Marketing Officer, Ian Davidson, who founded Davidson Organics, one of the largest cultivators in California; and, Chief Operations Officer, Ryan Tiberti, who has developed, built, and operated several multi-million dollar cannabis firms in the U.S.

Click here to receive Segra International updates prior to the company going public.

Disclaimer 

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading